BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25744348)

  • 1. Pathology and genetics of diffuse gliomas in adults.
    Komori T
    Neurol Med Chir (Tokyo); 2015; 55(1):28-37. PubMed ID: 25744348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathology and Genetics of Diffuse Gliomas in Adults.
    Komori T
    Neurol Med Chir (Tokyo); 2015; 55 Suppl 1():28-37. PubMed ID: 26236800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology and Genetics of Gliomas.
    Komori T; Muragaki Y; Chernov MF
    Prog Neurol Surg; 2018; 31():1-37. PubMed ID: 29393190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
    Marko NF; Prayson RA; Barnett GH; Weil RJ
    Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histological and molecular classification of gliomas].
    Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
    Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetics of gliomas.
    Appin CL; Brat DJ
    Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.
    Appin CL; Brat DJ
    Adv Anat Pathol; 2015 Jan; 22(1):50-8. PubMed ID: 25461780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further understanding of the pathology of glioma: implications for the clinic.
    Camelo-Piragua S; Kesari S
    Expert Rev Neurother; 2016 Sep; 16(9):1055-65. PubMed ID: 27228211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Update on the 2016 WHO classification of tumors of the central nervous system - Part 1: Diffusely infiltrating gliomas].
    Švajdler M; Rychlý B; Zámečník J; Švajdler P
    Cesk Patol; 2017; 53(1):12-21. PubMed ID: 28248117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.
    Wood MD; Halfpenny AM; Moore SR
    Diagn Pathol; 2019 Apr; 14(1):29. PubMed ID: 30967140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
    Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
    Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.
    Thon N; Eigenbrod S; Grasbon-Frodl EM; Ruiter M; Mehrkens JH; Kreth S; Tonn JC; Kretzschmar HA; Kreth FW
    J Neuropathol Exp Neurol; 2009 Nov; 68(11):1219-28. PubMed ID: 19816195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification].
    Figarella-Branger D; Chappe C; Padovani L; Mercurio S; Colin C; Forest F; Bouvier C
    Bull Cancer; 2013; 100(7-8):715-26. PubMed ID: 23831947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system.
    Gritsch S; Batchelor TT; Gonzalez Castro LN
    Cancer; 2022 Jan; 128(1):47-58. PubMed ID: 34633681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioma biology and molecular markers.
    Cohen AL; Colman H
    Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
    Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
    J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
    Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
    Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.